Valuation Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.71 USD | -2.12% |
|
+3.33% | +28.74% |
| 07-07 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 06-11 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
Company Valuation: Scholar Rock Holding Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 872.1 | 467.6 | 1,356 | 4,046 | 4,493 | 6,795 | - | - |
| Change | - | -46.39% | 190.08% | 198.32% | 11.06% | 51.23% | - | - |
| Enterprise Value (EV) 1 | 709.3 | 414 | 1,304 | 3,918 | 4,270 | 6,493 | 6,440 | 6,503 |
| Change | - | -41.63% | 215.07% | 200.38% | 8.97% | 52.08% | -0.82% | 0.98% |
| P/E | -6.92x | -4x | -9.45x | -17.5x | -13.4x | -17.8x | -22.2x | -36.7x |
| PBR | 5.3x | 2.07x | 6.96x | 11x | 20.6x | 27.5x | 26.8x | 33.3x |
| PEG | - | 0.1x | 0.8x | -0.7x | -0.4x | 5.26x | 1.1x | 0.9x |
| Capitalization / Revenue | 46.3x | 14.1x | - | - | - | 1,044x | 45.5x | 19.4x |
| EV / Revenue | 37.7x | 12.5x | - | - | - | 997x | 43.1x | 18.6x |
| EV / EBITDA | -5.57x | - | - | - | -11.1x | -15.2x | -22x | -66.6x |
| EV / EBIT | -5.46x | -3.08x | -7.62x | -15.5x | -11.1x | -15.1x | -19.1x | -35.1x |
| EV / FCF | -5.37x | -3.1x | -8.98x | -19.5x | -14.2x | -20x | -28.9x | -72.9x |
| FCF Yield | -18.6% | -32.3% | -11.1% | -5.13% | -7.04% | -5.01% | -3.46% | -1.37% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 | -3.179 | -2.552 | -1.546 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18.82 | 33.19 | - | - | - | 6.512 | 149.5 | 350.1 |
| EBITDA 1 | -127.3 | - | - | - | -383 | -426.8 | -292.4 | -97.64 |
| EBIT 1 | -129.9 | -134.4 | -171.3 | -252.1 | -384.6 | -430.4 | -337.6 | -185.1 |
| Net income 1 | -131.8 | -134.5 | -165.8 | -246.3 | -377.9 | -409.7 | -356.3 | -209.9 |
| Net Debt 1 | -162.8 | -53.53 | -51.84 | -127.7 | -223.8 | -302.1 | -355.6 | -292.4 |
| Reference price 2 | 24.84 | 9.05 | 18.80 | 43.22 | 44.05 | 56.71 | 56.71 | 56.71 |
| Nbr of stocks (in thousands) | 35,108 | 51,663 | 72,143 | 93,615 | 102,007 | 119,828 | - | - |
| Announcement Date | 7/3/22 | 7/3/23 | 19/3/24 | 27/2/25 | 3/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -17.84x | 997.17x | -15.21x | -.--% | 6.8B | |
| 32.72x | 8.29x | 25.68x | 0.06% | 54.63B | |
| 20.57x | 6.35x | 13.84x | 1.56% | 54.88B | |
| -44.31x | 14.51x | -42.32x | -.--% | 25.06B | |
| -18.2x | 4.33x | -7.58x | -.--% | 23.14B | |
| 25x | 4.91x | 12.91x | -.--% | 19.88B | |
| 24.48x | 4.79x | 15.58x | -.--% | 17.55B | |
| 49.34x | 20.07x | 51.69x | 0.07% | 16.5B | |
| 17.75x | 5.16x | 12.01x | -.--% | 14.2B | |
| -539.24x | 37.03x | -4128.99x | -.--% | 15.36B | |
| Average | -44.97x | 110.26x | -406.24x | 0.17% | 24.8B | |
| Weighted average by Cap. | -20.27x | 37.08x | -246.19x | 0.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SRRK Stock
- Valuation Scholar Rock Holding Corporation
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
